Summary
Gilead Sciences, Inc. reported a strong first quarter for 2005, with total revenues increasing by 39% year-over-year to $430.4 million. This growth was primarily driven by a significant 45% surge in product sales, reaching $400.2 million. The company's HIV product franchise, including Viread, Emtriva, and the growing Truvada, was a key growth engine, demonstrating a 47% increase in sales. AmBisome and Hepsera also showed robust growth. Net income rose to $157.1 million, or $0.34 per diluted share, from $114.4 million, or $0.25 per diluted share, in the prior year's first quarter. The company highlighted strategic advancements, including the initiation of collaborative activities for a fixed-dose combination of Truvada and Bristol Myers Squibb's Sustiva, and a new licensing agreement with Japan Tobacco for an HIV integrase inhibitor. Gilead's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $1.47 billion at the end of the quarter. The company anticipates continued growth, with full-year revenue projections for its HIV products between $1.225 billion and $1.275 billion.
Key Highlights
- 1Total revenues surged 39% to $430.4 million in Q1 2005 compared to Q1 2004.
- 2Product sales increased by 45% to $400.2 million, driven by strong performance in HIV products.
- 3HIV product sales grew by 47%, with Truvada showing significant growth since its 2004 launch.
- 4Net income increased to $157.1 million ($0.34 per diluted share) from $114.4 million ($0.25 per diluted share) in the prior year.
- 5Cash, cash equivalents, and marketable securities grew to $1.47 billion, indicating strong liquidity.
- 6Entered into a licensing agreement with Japan Tobacco for a novel HIV integrase inhibitor.
- 7Initiated collaborative activities for a fixed-dose combination of Truvada and Sustiva with Bristol Myers Squibb.